Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Padsevonil cardiac safety study in healthy volunteers
NCT04126343Phase 1Terminated
- Sponsor
- UCB
- Start
- Oct 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of padsevonil in focal onset seizure (3 arms), sponsored by UCB. Primary endpoint: Placebo-corrected Change From Baseline in QTcF on Day 8 for Padsevonil. Started Oct 2019; status: terminated.
02
Drugs
padsevonil
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT04126343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126343.